Handelsavisen
prelaunch
Companies Healthcare BRGX.PK
BR
BRGX.PK OTC Diversified Medical Equipment & Supplies

Brgx.Pk

$0,01
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-67,1 %
ROE
34,0 %
Net margin
-83,2 %
Debt / equity
-0,49
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

BRGX.PK operates in the healthcare services and equipment industry, focusing on medical equipment, supplies, and distribution.

Business. BRGX.PK operates in the healthcare services and equipment industry, focusing on medical equipment, supplies, and distribution.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
34,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BRGX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BRGX.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    BRGX.PK operates in the healthcare services and equipment industry, focusing on medical equipment, supplies, and distribution.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    The company's capital structure is highly leveraged, with total liabilities of $4.95 billion and total equity of -$4.54 billion, resulting in a negative debt-to-equity ratio of -0.49. Liquidity is constrained, as evidenced by a current ratio of 0.06 and only $69.38 million in cash and equivalents. The negative net income of -$1.54 billion and a free cash flow of -$1.53 billion indicate significant cash outflows, which could pressure the company's ability to meet short-term obligations.

    Profitability metrics are mixed. The company reports a gross profit of $1.5 billion, but this is offset by an operating loss of -$1.24 billion and a net loss of -$1.54 billion. Return on equity is positive at 34.02%, but this is misleading due to the negative equity base. Return on assets is negative at -3.76%, indicating poor asset utilization and underperformance relative to industry norms.

    The company's revenue concentration is not disclosed in the available data, but the negative equity and high leverage suggest a potential overreliance on a narrow set of revenue streams or geographic regions. The lack of segment or geographic breakdown in the financial data limits the ability to assess diversification risk.

    The company's growth trajectory is uncertain. The available data does not provide forward-looking revenue guidance or historical growth rates, but the current financial performance suggests a challenging operating environment. The negative operating and net income, combined with a free cash flow deficit, indicate that the company is not generating sufficient cash to sustain operations or fund growth initiatives.

    Risk factors include liquidity constraints, with a current ratio of 0.06 and negative net cash after subtracting total debt. The dilution risk is currently assessed as low, but the company's negative equity and high leverage could increase the likelihood of future equity issuances. The risk assessment also highlights the need for close monitoring of the company's capital structure and cash flow generation.

    Recent events, including filings and transcripts, are not detailed in the available data. However, the company's financial performance and capital structure suggest that it may be under pressure to address liquidity and profitability concerns. The lack of disclosed capital expenditures and the negative free cash flow indicate that the company is not investing in growth or operational improvements.

    Key takeaways
    • The company is highly leveraged with a negative equity position and a debt-to-equity ratio of -0.49.
    • Despite a gross profit of $1.5 billion, the company reports a net loss of -$1.54 billion and a free cash flow deficit of -$1.53 billion.
    • The company's liquidity is constrained, with a current ratio of 0.06 and only $69.38 million in cash and equivalents.
    • The company's return on equity is positive at 34.02%, but this is misleading due to the negative equity base.
    • The company's growth trajectory is uncertain, with no disclosed forward-looking guidance or historical growth rates.
    • The company faces liquidity and profitability risks, with a need to address its capital structure and cash flow generation.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,01
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$4.5M
    Net cash
    -$2.1M
    Current ratio
    0.1
    Debt / equity
    -0.5
    ROA
    -3.8%
    ROE
    34.0%
    Cash conversion
    -3.0%
    CapEx / revenue
    -3.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setBRGX 0,0% · rank #77 of 84

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs BRGX · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-67,1 %Bottom quartile
    Net Margin-83,2 %Bottom quartile
    ROE34,0 %Best in class
    Capex / Rev-3,2 %Below median
    D/E-0,49Best in class
    Cash Conv-0,03Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • BRGX.PK Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BRGX.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 112.0%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -19.2%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 4.1%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -9.3%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 100.0%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 100.0%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -48.5%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -95.2%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): -1.09xDerived (calculated)
    • Current ratio (FY 2025-12-31): 0.06xDerived (calculated)
    • Return on assets (FY 2025-12-31): -375.6%Derived (calculated)
    • Return on equity (FY 2025-12-31): 34.0%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 27.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 93.3%Derived (calculated)
    • Gross margin (FY 2025-12-31): 81.1%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -34.3%Derived (calculated)
    • Net margin (FY 2025-12-31): -83.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -20.8%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 94.5%Derived (calculated)
    • Total assets (annual): USD 410.99KSEC XBRL filing
    • Operating cash flow (annual): USD 38.97KSEC XBRL filing
    • Shareholders' equity (annual): USD -4.54MSEC XBRL filing
    • Current liabilities (annual): USD 4.07MSEC XBRL filing
    • Long-term debt (annual): USD 1.19MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage